We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $3.89B
1-Year Est. Return 201.1%
This Fund
S&P 500
This Quarter Est. Return
+5.39%
1 Year Est. Return
+201.1%
3 Year Est. Return
+879.31%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.51B
AUM Growth
-$169M
Cap. Flow
-$38.2M
Cap. Flow %
-2.54%
Top 10 Hldgs %
63.08%
Holding
56
New
8
Increased
10
Reduced
5
Closed
4

Top Buys

1
MIRM icon
Mirum Pharmaceuticals
MIRM
+$57.8M
2
APLS
Apellis Pharmaceuticals
APLS
+$27M
3
RCKT icon
Rocket Pharmaceuticals
RCKT
+$25.5M
4
BBIO icon
BridgeBio Pharma
BBIO
+$20.9M
5
ANTX icon
AN2 Therapeutics
ANTX
+$15.7M

Top Sells

1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$167M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$58.8M
3
MORF
Morphic Holding, Inc. Common Stock
MORF
+$15.2M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$10.2M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$6.15M

Sector Composition

1 Healthcare 99.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PASG icon
51
Passage Bio
PASG
$15.7M
$1.16M 0.08%
87,911
-4,589
-5% -$75.4K
NAMSW icon
52
NewAmsterdam Pharma Warrant
NAMSW
$951K 0.06%
500,333
– –
IMVT icon
53
Immunovant
IMVT
$8.26B
– –
-300,000
Closed -$5.69M
MORF
54
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-265,511
Closed -$15.2M
RETA
55
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-100,430
Closed -$10.2M
KDNY
56
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-4,345,559
Closed -$167M
1 2
3

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $3.88B AUM 23.82% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
CCM
Channing Capital Management Chicago, Illinois $3.91B AUM 34.32% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
AA
Alesco Advisors Pittsford, New York $3.92B AUM 15.21% 1-Year Est. Return
DACG
Donor Advised Charitable Giving San Francisco, California $3.92B AUM 59.92% 1-Year Est. Return

Frazier Life Sciences Management's Q3 2023 Portfolio in Review

As of Q3 2023, Frazier Life Sciences Management held 56 positions worth $1.51B, down 10% from $1.67B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Frazier Life Sciences Management's Q3 2023 filing shows 8 new, 10 increased, 5 reduced and 4 closed positions. Its largest new stake was Apellis Pharmaceuticals: 614,043 shares worth $23.4M. The largest sale was Chinook Therapeutics, Inc. Common Stock, an estimated $167M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

  • Frazier Life Sciences Management's largest Q3 2023 buy was Apellis Pharmaceuticals: 614,043 shares worth $23.4M.
  • Frazier Life Sciences Management added most to Mirum Pharmaceuticals in Q3 2023, an estimated $57.8M increase.
  • Frazier Life Sciences Management's biggest Q3 2023 reduction was Syndax Pharmaceuticals, cutting an estimated $58.8M.
  • Frazier Life Sciences Management fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $167M.
  • Frazier Life Sciences Management's ten largest holdings make up 63% of its $1.51B portfolio in Q3 2023.
  • Frazier Life Sciences Management opened 8 new positions and closed 4 in Q3 2023.
  • Frazier Life Sciences Management's portfolio value fell 10% quarter-over-quarter to $1.51B.

Based on Frazier Life Sciences Management's 13F filing for Q3 2023, filed 14 Nov 2023.